Biosupply Trends Marketplace News
Monday, August 19, 2019
Banner Image - Patient Safety, Product Integrity, Fair Pricing
biosupply button green pixel top of biosupply button Spacer image top of Verified Inventory Program button
Biosupply, place your product order Spacer image MyFluVaccine, place your vaccine order Spacer image Verified Inventory Program, sign up for streamlined inventory

CDC Recommends Hepatitis A Vaccination For 2- to 18-Year-Olds

Main article image
 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

Due to a surge in hepatitis A cases in the U.S., the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices is recommending children and adolescents who have not previously received a hepatitis A vaccine be vaccinated at any age from 2 years through 18 years. read more ]

Flu Pamphlet Impacts Parents' Decision to Vaccinate Kids

A new study by researchers at Columbia University has found handing a pamphlet about influenza (flu) to parents in pediatricians' waiting rooms can have a significant impact on increasing the uptake of the flu vaccine. read more ]

ACIP Raises Recommended Age for HPV Vaccine
in Men Up to Age 26

In June, the Advisory Committee on Immunization Practices (ACIP) raised the recommended vaccination age for the human papillomavirus (HPV) vaccine from 21 years old to 26 years old, making it the same recommendation for women. The recommendation to equalize the age is intended to make it easier for physicians.
read more ]

Industry News

 
Industry News Image
 

From Grifols

The U.S. Food and Drug Administration has approved Grifols' Xembify (immune globulin subcutaneous 20%) to treat primary immunodeficiency disease patients 2 years and older. The product will be launched in the U.S. in the fourth quarter of this year. read more ]

From Dova Pharmaceuticals

The U.S. Food and Drug Administration has approved an expanded indication for Dova Pharmaceuticals' Doptelet (avatrombopag) to treat adults with chronic immune thrombocytopenia who had an insufficient response to a previous treatment.
 [ read more ]

From Jeffrey Modell Foundation

Jeffrey Modell Foundation cofounders Fred and Vicki Modell in conjunction with an award-winning film production team have produced "Do Something: The Jeffrey Modell Story" now available on DVD, digital and video-on-demand platforms. The film's goals are to spread awareness about primary immunodeficiency disorders, to educate those who are unfamiliar with these rare conditions and to provide a strong sense of community for patients and their families who may feel underrepresented or misunderstood. read more ]

IVIG & Albumin Supply Index

IVIG and Albumin Days On Hand
     
 
 
 
     

What's New at FFF

KOATE-DVI  (GRIFOLS)

KOATE-DVI is indicated for the treatment of hemophilia A in which there is a demonstrated deficiency of activity of clotting factor VIII. Koate-DVI provides a means of temporarily replacing the missing clotting factor to control or prevent bleeding episodes, or to perform emergency and elective surgery on individuals with hemophilia. It is supplied in a kit containing one single-use vial of Koate-DVI lyophilized powder, one vial of sterile water for injection, USP, one sterile double-ended transfer needle, one sterile filter needle, and one sterile administration set.

For more information about KOATE-DVI, log in to biosupply.fffenterprises.com

ELCYS  (EXELA PHARMA SCIENCES)

ELCYS (cysteine hydrochloride injection) is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN) and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. Each 10 mL of ELCYS contains 500 mg of cysteine hydrochloride, USP (equivalent to 345 mg of cysteine) in water for injection. Sodium hydroxide and/or hydrochloric acid are used as needed to adjust the pH range from 1.0 to 2.5.

For more information about ELCYS, log in to biosupply.fffenterprises.com

APLISOL  (PAR PHARMACEUTICAL INC.)

APLISOL (tuberculin PPD, diluted) is indicated as an aid in the detection of infection with Mycobacterium tuberculosis. It is ready for immediate use without further dilution in 1 mL (10 tests) multiple-dose vials and 5 mL (50 tests) multiple-dose vials.

For more information about APLISOL, log in to biosupply.fffenterprises.com

CEFTAZIDIME USP AND DEXTROSE USP  (B. BRAUN MEDICAL INC.)

CEFTAZIDIME for injection USP and DEXTROSE injection USP are cephalosporin antibacterials indicated for treatment of the following infections caused by susceptible isolates of the designated microorganisms: lower respiratory tract infections, skin and skin-structure infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections and central nervous system infections. They are supplied in 1 gram in 50 mL and 2 grams in 50 mL DUPLEX containers.

For more information about CEFTAZIMIDE and DEXTROSE, log in to biosupply.fffenterprises.com

CEFTRIAXONE AND DEXTROSE  (B. BRAUN MEDICAL INC.)

Ceftriaxone for injection and Dextrose injection are cephalosporin antibacterials indicated for treatment of the following infections caused by susceptible isolates of the designated bacteria: lower respiratory tract infections, skin and skin structure infections, complicated and uncomplicated urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis and surgical prophylaxis. They should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Both are supplied in dual chamber, single-use containers consisting of 1 gram ceftriaxone for injection and 50 mL of 3.74% dextrose injection; and 2 grams ceftriaxone for injection and 50 mL of 2.22% dextrose injection.

For more information about CEFTRIAXONE and DEXTROSE, log in to biosupply.fffenterprises.com

CEFOTETAN AND DEXTROSE  (B. BRAUN MEDICAL INC.)

CEFOTETAN for injection USP and DEXTROSE injection USP is indicated for therapeutic treatment of the following infections when caused by susceptible strains of the designated organisms (see prescribing information): 1) urinary tract infections, 2) lower respiratory tract infections, 3) skin and skin structure infections, 4) gynecologic infections, 5) intra-abdominal infections and 6) bone and joint infections. They are supplied as a sterile, nonpyrogenic, single use packaged combination of Cefotetan disodium and Dextrose injection (diluent) in the DUPLEX sterile container.

For more information about CEFOTETAN AND DEXTROSE, log in to biosupply.fffenterprises.com

MEROPENEM AND SODIUM CHLORIDE  (B. BRAUN MEDICAL INC.)

MEROPENEM for injection USP and SODIUM CHLORIDE injection USP is a penem antibacterial indicated as single agent therapy for the treatment of complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older requiring the full adult dose only); complicated intra-abdominal infections (adult patients and pediatric patients 3 months of age and older requiring the full adult dose only); and bacterial meningitis (pediatric patients 3 months of age and older requiring the full adult dose only). They are supplied as 500 mg Meropenem for injection USP and 50 mL sodium chloride injection 0.9% USP, and 1 gram Meropenem for injection USP and 50 mL sodium chloride injection 0.9% USP in DUPLEX containers.

For more information about MEROPENEM AND SODIUM CHLORIDE, log in to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective July 1, 2019, through Sept. 30, 2019.

 
Calculate your current medicare IVIG/SCIG Rates
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Flebogamma J1572 $71.71 $70.56
Gammagard S/D J1566 $124.44 $122.44
Gammaplex J1557 $92.06 $90.59
Octagam J1568 $64.94 $63.90
Privigen J1459 $81.21

$79.90

SCIG
CUVITRU J1555 $138.56 $136.34
Hizentra J1559 $101.89 $100.26
HyQvia J1575 $140.24 $137.99
IVIG / SCIG
Gammagard Liquid J1569 $81.93 $80.62
Gammaked J1561 $77.29 $76.05
Gamunex-C J1561 $77.29 $76.05

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 
Log in to BioSupply for Immune Globulin Products

Resources

FFF customers may order the following complementary resources to help you with your practice:

Seasonal Flu Poster flu myths and facts brochure
immune globulin reference charts
•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to IG Living
IG Living Magazine cover
BioSupplyTrends Quarterly Magazine cover

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Subscribe to Biosupply Trends Quarterly Magazine
small Biosupply logo small MyFluVaccine logo Verified Inventory Program logo
Home | About | Advertise | Subscribe | Contact – ©FFF Enterprises, Inc.